Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Olorofim (Primary)
- Indications Aspergillosis; Mycoses
- Focus Therapeutic Use
- Acronyms FORMULA-OLS
- Sponsors F2G
- 11 Nov 2019 According to a F2G media release,26 centres are currently open in six countries (AU, BE, ES, NL, USA, IS) and a further 20 will open in 2019/2020.
- 07 Jan 2019 According to a F2G media release, there will be study sites across at least 6 countries. With 12 centres open in 5 countries (AU, BE, ES, NL, US), investigators in the study are recruiting patients well ahead of schedule.A further 20 centres will open in 2019.
- 21 Jun 2018 New trial record